Trends in the consumption rates of benzodiazepines and benzodiazepine-related drugs in the health region of Lleida from 2002 to 2015
Background The high prevalence and long-term use of benzodiazepines (BZDs) treatment are debated topics because of the risk they can cause to the patients. Despite the current information on the risk-benefit balance of these drugs, their consumption remains particularly high. We determined the trend...
Gespeichert in:
| Veröffentlicht in: | BMC public health Jg. 20; H. 1; S. 818 - 9 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
London
BioMed Central
01.06.2020
BioMed Central Ltd BMC |
| Schlagworte: | |
| ISSN: | 1471-2458, 1471-2458 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Background
The high prevalence and long-term use of benzodiazepines (BZDs) treatment are debated topics because of the risk they can cause to the patients. Despite the current information on the risk-benefit balance of these drugs, their consumption remains particularly high. We determined the trend in the consumption prevalence of benzodiazepines (BZDs) and drugs related to BZDs (Z-drugs) in the population of the Health Region of Lleida to explore patterns of use and the associated characteristics associated between 2002 and 2015.
Methods
An analysis of secular trends was carried out between 2002 and 2015; the databased included all individuals from the Health Region of Lleida, which had 358,157 inhabitants in 2015, that consumed BZDs. The consumption of BZDs was evaluated using prescription billing data from the Public Health System. All types of BZDs and BZD analogues that had been approved by the drug agency were included. Trends by age and sex were investigated.
Results
Over the whole study period, a total of 161,125 individuals accounted for 338,148 dispensations. Overall, 59% were women, and the mean age was 56 years. The dispensing prevalence of BZDs use in 2015 was 14.2% overall —18.8% in women and 9.6% in men—and was 36% in those over 65 years. According to the half-life of BZDs, the prevalence of short-intermediate BZD use, intermediate-long BZD use, and Z-drugs use was 9.7, 5.5 and 0.8%, respectively. The evolution of the annual prevalence of BZD dispensing showed a progressive decline, from 15.3% in 2002 to 14.2% in 2015, which was attributed to a decrease in the consumption of intermediate-long half-life BZDs (8.0% vs. 5.5%) and Z-drugs (1.4% vs. 0.8%).
Conclusion
The dispensing prevalence of BZDs and Z-drugs was high, although a small reduction was observed during this time period. The dispensing prevalence was especially high in the population over 65, despite the risk of cognitive decline and falls. Integral actions are required to lower the BZD prescription rate. |
|---|---|
| AbstractList | The high prevalence and long-term use of benzodiazepines (BZDs) treatment are debated topics because of the risk they can cause to the patients. Despite the current information on the risk-benefit balance of these drugs, their consumption remains particularly high. We determined the trend in the consumption prevalence of benzodiazepines (BZDs) and drugs related to BZDs (Z-drugs) in the population of the Health Region of Lleida to explore patterns of use and the associated characteristics associated between 2002 and 2015.BACKGROUNDThe high prevalence and long-term use of benzodiazepines (BZDs) treatment are debated topics because of the risk they can cause to the patients. Despite the current information on the risk-benefit balance of these drugs, their consumption remains particularly high. We determined the trend in the consumption prevalence of benzodiazepines (BZDs) and drugs related to BZDs (Z-drugs) in the population of the Health Region of Lleida to explore patterns of use and the associated characteristics associated between 2002 and 2015.An analysis of secular trends was carried out between 2002 and 2015; the databased included all individuals from the Health Region of Lleida, which had 358,157 inhabitants in 2015, that consumed BZDs. The consumption of BZDs was evaluated using prescription billing data from the Public Health System. All types of BZDs and BZD analogues that had been approved by the drug agency were included. Trends by age and sex were investigated.METHODSAn analysis of secular trends was carried out between 2002 and 2015; the databased included all individuals from the Health Region of Lleida, which had 358,157 inhabitants in 2015, that consumed BZDs. The consumption of BZDs was evaluated using prescription billing data from the Public Health System. All types of BZDs and BZD analogues that had been approved by the drug agency were included. Trends by age and sex were investigated.Over the whole study period, a total of 161,125 individuals accounted for 338,148 dispensations. Overall, 59% were women, and the mean age was 56 years. The dispensing prevalence of BZDs use in 2015 was 14.2% overall -18.8% in women and 9.6% in men-and was 36% in those over 65 years. According to the half-life of BZDs, the prevalence of short-intermediate BZD use, intermediate-long BZD use, and Z-drugs use was 9.7, 5.5 and 0.8%, respectively. The evolution of the annual prevalence of BZD dispensing showed a progressive decline, from 15.3% in 2002 to 14.2% in 2015, which was attributed to a decrease in the consumption of intermediate-long half-life BZDs (8.0% vs. 5.5%) and Z-drugs (1.4% vs. 0.8%).RESULTSOver the whole study period, a total of 161,125 individuals accounted for 338,148 dispensations. Overall, 59% were women, and the mean age was 56 years. The dispensing prevalence of BZDs use in 2015 was 14.2% overall -18.8% in women and 9.6% in men-and was 36% in those over 65 years. According to the half-life of BZDs, the prevalence of short-intermediate BZD use, intermediate-long BZD use, and Z-drugs use was 9.7, 5.5 and 0.8%, respectively. The evolution of the annual prevalence of BZD dispensing showed a progressive decline, from 15.3% in 2002 to 14.2% in 2015, which was attributed to a decrease in the consumption of intermediate-long half-life BZDs (8.0% vs. 5.5%) and Z-drugs (1.4% vs. 0.8%).The dispensing prevalence of BZDs and Z-drugs was high, although a small reduction was observed during this time period. The dispensing prevalence was especially high in the population over 65, despite the risk of cognitive decline and falls. Integral actions are required to lower the BZD prescription rate.CONCLUSIONThe dispensing prevalence of BZDs and Z-drugs was high, although a small reduction was observed during this time period. The dispensing prevalence was especially high in the population over 65, despite the risk of cognitive decline and falls. Integral actions are required to lower the BZD prescription rate. Abstract Background The high prevalence and long-term use of benzodiazepines (BZDs) treatment are debated topics because of the risk they can cause to the patients. Despite the current information on the risk-benefit balance of these drugs, their consumption remains particularly high. We determined the trend in the consumption prevalence of benzodiazepines (BZDs) and drugs related to BZDs (Z-drugs) in the population of the Health Region of Lleida to explore patterns of use and the associated characteristics associated between 2002 and 2015. Methods An analysis of secular trends was carried out between 2002 and 2015; the databased included all individuals from the Health Region of Lleida, which had 358,157 inhabitants in 2015, that consumed BZDs. The consumption of BZDs was evaluated using prescription billing data from the Public Health System. All types of BZDs and BZD analogues that had been approved by the drug agency were included. Trends by age and sex were investigated. Results Over the whole study period, a total of 161,125 individuals accounted for 338,148 dispensations. Overall, 59% were women, and the mean age was 56 years. The dispensing prevalence of BZDs use in 2015 was 14.2% overall —18.8% in women and 9.6% in men—and was 36% in those over 65 years. According to the half-life of BZDs, the prevalence of short-intermediate BZD use, intermediate-long BZD use, and Z-drugs use was 9.7, 5.5 and 0.8%, respectively. The evolution of the annual prevalence of BZD dispensing showed a progressive decline, from 15.3% in 2002 to 14.2% in 2015, which was attributed to a decrease in the consumption of intermediate-long half-life BZDs (8.0% vs. 5.5%) and Z-drugs (1.4% vs. 0.8%). Conclusion The dispensing prevalence of BZDs and Z-drugs was high, although a small reduction was observed during this time period. The dispensing prevalence was especially high in the population over 65, despite the risk of cognitive decline and falls. Integral actions are required to lower the BZD prescription rate. Background The high prevalence and long-term use of benzodiazepines (BZDs) treatment are debated topics because of the risk they can cause to the patients. Despite the current information on the risk-benefit balance of these drugs, their consumption remains particularly high. We determined the trend in the consumption prevalence of benzodiazepines (BZDs) and drugs related to BZDs (Z-drugs) in the population of the Health Region of Lleida to explore patterns of use and the associated characteristics associated between 2002 and 2015. Methods An analysis of secular trends was carried out between 2002 and 2015; the databased included all individuals from the Health Region of Lleida, which had 358,157 inhabitants in 2015, that consumed BZDs. The consumption of BZDs was evaluated using prescription billing data from the Public Health System. All types of BZDs and BZD analogues that had been approved by the drug agency were included. Trends by age and sex were investigated. Results Over the whole study period, a total of 161,125 individuals accounted for 338,148 dispensations. Overall, 59% were women, and the mean age was 56 years. The dispensing prevalence of BZDs use in 2015 was 14.2% overall --18.8% in women and 9.6% in men--and was 36% in those over 65 years. According to the half-life of BZDs, the prevalence of short-intermediate BZD use, intermediate-long BZD use, and Z-drugs use was 9.7, 5.5 and 0.8%, respectively. The evolution of the annual prevalence of BZD dispensing showed a progressive decline, from 15.3% in 2002 to 14.2% in 2015, which was attributed to a decrease in the consumption of intermediate-long half-life BZDs (8.0% vs. 5.5%) and Z-drugs (1.4% vs. 0.8%). Conclusion The dispensing prevalence of BZDs and Z-drugs was high, although a small reduction was observed during this time period. The dispensing prevalence was especially high in the population over 65, despite the risk of cognitive decline and falls. Integral actions are required to lower the BZD prescription rate. Keywords: Benzodiazepines, Sedative-hypnotics, Prescribing trends, Drug safety, Drug utilization Background The high prevalence and long-term use of benzodiazepines (BZDs) treatment are debated topics because of the risk they can cause to the patients. Despite the current information on the risk-benefit balance of these drugs, their consumption remains particularly high. We determined the trend in the consumption prevalence of benzodiazepines (BZDs) and drugs related to BZDs (Z-drugs) in the population of the Health Region of Lleida to explore patterns of use and the associated characteristics associated between 2002 and 2015. Methods An analysis of secular trends was carried out between 2002 and 2015; the databased included all individuals from the Health Region of Lleida, which had 358,157 inhabitants in 2015, that consumed BZDs. The consumption of BZDs was evaluated using prescription billing data from the Public Health System. All types of BZDs and BZD analogues that had been approved by the drug agency were included. Trends by age and sex were investigated. Results Over the whole study period, a total of 161,125 individuals accounted for 338,148 dispensations. Overall, 59% were women, and the mean age was 56 years. The dispensing prevalence of BZDs use in 2015 was 14.2% overall —18.8% in women and 9.6% in men—and was 36% in those over 65 years. According to the half-life of BZDs, the prevalence of short-intermediate BZD use, intermediate-long BZD use, and Z-drugs use was 9.7, 5.5 and 0.8%, respectively. The evolution of the annual prevalence of BZD dispensing showed a progressive decline, from 15.3% in 2002 to 14.2% in 2015, which was attributed to a decrease in the consumption of intermediate-long half-life BZDs (8.0% vs. 5.5%) and Z-drugs (1.4% vs. 0.8%). Conclusion The dispensing prevalence of BZDs and Z-drugs was high, although a small reduction was observed during this time period. The dispensing prevalence was especially high in the population over 65, despite the risk of cognitive decline and falls. Integral actions are required to lower the BZD prescription rate. The high prevalence and long-term use of benzodiazepines (BZDs) treatment are debated topics because of the risk they can cause to the patients. Despite the current information on the risk-benefit balance of these drugs, their consumption remains particularly high. We determined the trend in the consumption prevalence of benzodiazepines (BZDs) and drugs related to BZDs (Z-drugs) in the population of the Health Region of Lleida to explore patterns of use and the associated characteristics associated between 2002 and 2015. An analysis of secular trends was carried out between 2002 and 2015; the databased included all individuals from the Health Region of Lleida, which had 358,157 inhabitants in 2015, that consumed BZDs. The consumption of BZDs was evaluated using prescription billing data from the Public Health System. All types of BZDs and BZD analogues that had been approved by the drug agency were included. Trends by age and sex were investigated. Over the whole study period, a total of 161,125 individuals accounted for 338,148 dispensations. Overall, 59% were women, and the mean age was 56 years. The dispensing prevalence of BZDs use in 2015 was 14.2% overall --18.8% in women and 9.6% in men--and was 36% in those over 65 years. According to the half-life of BZDs, the prevalence of short-intermediate BZD use, intermediate-long BZD use, and Z-drugs use was 9.7, 5.5 and 0.8%, respectively. The evolution of the annual prevalence of BZD dispensing showed a progressive decline, from 15.3% in 2002 to 14.2% in 2015, which was attributed to a decrease in the consumption of intermediate-long half-life BZDs (8.0% vs. 5.5%) and Z-drugs (1.4% vs. 0.8%). The dispensing prevalence of BZDs and Z-drugs was high, although a small reduction was observed during this time period. The dispensing prevalence was especially high in the population over 65, despite the risk of cognitive decline and falls. Integral actions are required to lower the BZD prescription rate. |
| ArticleNumber | 818 |
| Audience | Academic |
| Author | Torres-Bondia, F. Galván, L. Buti, M. Barbé, F. Piñol-Ripoll, G. de Batlle, J. |
| Author_xml | – sequence: 1 givenname: F. surname: Torres-Bondia fullname: Torres-Bondia, F. organization: Pharmacy Department, Clinical Neuroscience Research, IRBLleida, Arnau de Vilanova University Hospital – sequence: 2 givenname: J. surname: de Batlle fullname: de Batlle, J. organization: Biomedical Research Networking Center in Respiratory Diseases (Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, CIBERES), Group of Translational Research in Respiratory Medicine, Arnau de Vilanova University Hospital and Santa Maria University Hospital, IRBLleida – sequence: 3 givenname: L. surname: Galván fullname: Galván, L. organization: Pharmacy Department, Servei Català de la Salut (Catalan Health Services) – sequence: 4 givenname: M. surname: Buti fullname: Buti, M. organization: Unitat d’Avaluació Clínica (Clinical Evaluation Unit), Institut Català de la Salut (Catalan Institute of Health) – sequence: 5 givenname: F. surname: Barbé fullname: Barbé, F. organization: Biomedical Research Networking Center in Respiratory Diseases (Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, CIBERES), Group of Translational Research in Respiratory Medicine, Arnau de Vilanova University Hospital and Santa Maria University Hospital, IRBLleida – sequence: 6 givenname: G. surname: Piñol-Ripoll fullname: Piñol-Ripoll, G. email: gerard_437302@hotmail.com organization: Unitat Trastorns Cognitius (Cognitive Disorders Unit), Clinical Neuroscience Research, IRBLleida, Santa Maria University Hospital |
| BookMark | eNp9kktr3DAUhU1JaR7tH-hK0E03TiXZ1mNTCKGPwEA36VrI0pVHwZamkl3orPPDq4nT0gklCCFxdc7HFeeeVychBqiqtwRfEiLYh0yoELLGFNdYSNHW-xfVGWk5qWnbiZN_7qfVec53GBMuOvqqOm1oKzjuxFl1f5sg2Ix8QPMWkIkhL9Nu9jGgpGfIKDrUQ9hH6_Uedj6Ukg72Sa1OMBa1RTYtw1_YFvQ4b1GC4YAroM0I3mrkUpwQxZiiOZaTdK-rl06PGd48nhfV98-fbq-_1ptvX26urza1YZTONWUOC8bL7rDj0gFAb0zfipY71jcgoeks6ZnUpGMgG82lYEC6DmPdWymai-pm5dqo79Qu-UmnXypqrx4KMQ1Kp9mbERTl0ODO9pRT0zaO96QhFAizXNuWOlNYH1fWbuknsAbCnPR4BD1-CX6rhvhTccpKw6QA3j8CUvyxQJ7V5LOBcdQB4pIVbbEkkpT4ivTdKh10ac0HFwvRHOTqilHeCMp5W1SX_1GVZWHyJVhwvtSPDGI1mBRzTuCU8bM-ZF-MflQEq8OcqXXOVJkz9TBnal-s9In1z8efNTWrKRdxGCCpu7ikUBJ_zvUbA4zmwA |
| CitedBy_id | crossref_primary_10_3390_separations11060169 crossref_primary_10_3390_ijerph192315902 crossref_primary_10_3390_ijerph191811426 crossref_primary_10_3389_fneur_2022_874724 crossref_primary_10_1016_j_biopha_2023_115950 crossref_primary_10_1186_s12877_021_02715_8 crossref_primary_10_1016_j_jpsychires_2023_11_042 crossref_primary_10_3389_fphar_2025_1547488 crossref_primary_10_1155_adpp_1404995 crossref_primary_10_1176_appi_focus_19203 crossref_primary_10_1093_ageing_afac060 crossref_primary_10_4102_sajpsychiatry_v30i0_2181 crossref_primary_10_1111_dar_13561 crossref_primary_10_1016_j_bbrc_2024_150218 crossref_primary_10_1177_00031348211011114 crossref_primary_10_1186_s12889_022_13217_6 crossref_primary_10_3389_fpsyt_2020_595584 crossref_primary_10_22159_ajpcr_2025v18i5_54402 crossref_primary_10_3390_jcm12103389 crossref_primary_10_3389_fphar_2023_1157231 crossref_primary_10_1016_j_cyto_2025_156976 crossref_primary_10_4103_ijcm_ijcm_618_22 crossref_primary_10_1155_2024_5448587 crossref_primary_10_3390_healthcare9121724 crossref_primary_10_1038_s41398_021_01718_8 crossref_primary_10_1007_s11469_021_00636_6 crossref_primary_10_1016_j_archger_2020_104209 crossref_primary_10_1016_j_jsps_2023_06_003 crossref_primary_10_1186_s12889_025_21980_5 crossref_primary_10_3389_fpubh_2022_1014734 crossref_primary_10_1038_s41598_022_26412_7 crossref_primary_10_1080_02813432_2025_2475300 crossref_primary_10_1007_s00737_023_01360_x crossref_primary_10_1016_j_psychres_2024_115800 crossref_primary_10_2217_pgs_2022_0161 crossref_primary_10_1007_s00406_023_01680_0 crossref_primary_10_3390_pharmacy10050120 crossref_primary_10_3390_pharmaceutics15020538 crossref_primary_10_1371_journal_pone_0284389 crossref_primary_10_1177_00207640251331898 crossref_primary_10_1016_j_jad_2020_12_073 crossref_primary_10_1093_ijnp_pyab073 crossref_primary_10_3389_fpsyt_2022_915823 crossref_primary_10_56294_hl2025597 crossref_primary_10_3390_nano15110827 crossref_primary_10_1039_D1RA08949H |
| Cites_doi | 10.9778/cmajo.20130076 10.1023/A:1008636707219 10.3399/bjgp14X677176 10.1111/jgs.13057 10.1097/00004714-199904000-00007 10.1016/S0895-4356(97)00238-2 10.3109/10826084.2014.980952 10.1016/j.jagp.2018.10.017 10.3399/bjgp11X593857 10.1002/pds.1827 10.1002/pds.4123 10.1002/pds.4551 10.1007/s002280100326 10.1007/s00228-004-0808-2 10.1007/s00127-011-0344-1 10.3399/bjgp16X685213 10.1136/bmj.307.6900.363 10.1111/bcpt.12684 10.4321/S1135-57272013000300004 10.1017/S0714980812000232 10.1111/bcp.13570 10.1016/j.euroneuro.2012.05.004 10.1097/YIC.0b013e328105e0f2 10.1016/j.janxdis.2011.01.002 10.1176/appi.ps.201200089 10.1159/000434755 10.1016/j.genhosppsych.2006.05.008 10.1007/s00213-016-4312-z 10.1002/pds.3825 10.1016/j.eurger.2012.04.007 10.2165/00002512-200320110-00004 10.1002/pds.1344 10.1111/jgs.13666 10.1007/s00228-011-1188-z 10.1111/jgs.15292 10.1007/s00228-015-1955-3 10.1007/s00228-007-0349-6 10.3390/jcm7020017 10.12788/jhm.2739 10.1111/acps.12858 10.1016/j.psychres.2016.01.040 10.22374/1710-6222.26.1.3 10.1108/14664100110408608 10.1002/da.20653 10.1136/bmj.320.7231.341 10.1517/14740338.3.5.485 10.1007/s11606-007-0205-5 10.1111/j.1360-0443.2011.03563.x 10.1007/s00213-002-1376-8 10.4088/JCP.v63n0912 10.1016/j.jad.2008.01.011 10.1002/pds.1063 10.1001/jamapsychiatry.2014.1763 10.1186/s12877-016-0363-6 10.1176/ajp.2007.164.2.276 10.1016/j.jclinepi.2004.10.012 10.1192/bjp.bp.113.126003 10.1111/j.1365-2869.2009.00769.x 10.1111/jgs.12093 10.1111/j.1467-842X.2000.tb00715.x 10.1007/s11606-019-05098-0 10.1007/s40266-018-0544-4 10.1002/pds.1756 10.1002/pds.3951 10.1016/j.addbeh.2012.05.017 10.5430/jer.v2n1p80 10.1046/j.1532-5415.2002.50004.x 10.1176/appi.ps.201700095 10.1007/s11606-006-0021-3 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2020 COPYRIGHT 2020 BioMed Central Ltd. |
| Copyright_xml | – notice: The Author(s) 2020 – notice: COPYRIGHT 2020 BioMed Central Ltd. |
| DBID | C6C AAYXX CITATION 7X8 5PM DOA |
| DOI | 10.1186/s12889-020-08984-z |
| DatabaseName | Springer Nature OA Free Journals (WRLC) CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Public Health |
| EISSN | 1471-2458 |
| EndPage | 9 |
| ExternalDocumentID | oai_doaj_org_article_27e305db272c43f7b1312e16d7ad42fc PMC7268471 A627382774 10_1186_s12889_020_08984_z |
| GeographicLocations | Spain |
| GeographicLocations_xml | – name: Spain |
| GrantInformation_xml | – fundername: Generalitat de Catalunya (ES) grantid: PERIS 2016: SLT002/16/00364 – fundername: ; grantid: PERIS 2016: SLT002/16/00364 |
| GroupedDBID | --- 0R~ 23N 2WC 2XV 44B 53G 5VS 6J9 6PF 7X7 7XC 88E 8C1 8FE 8FG 8FH 8FI 8FJ A8Z AAFWJ AAJSJ AASML AAWTL ABDBF ABJCF ABUWG ACGFO ACGFS ACIHN ACIWK ACPRK ACUHS ADBBV ADUKV AEAQA AENEX AEUYN AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AN0 AOIJS ATCPS BAPOH BAWUL BCNDV BENPR BFQNJ BGLVJ BHPHI BMC BNQBC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EMB EMK EMOBN ESTFP ESX F5P FYUFA GROUPED_DOAJ GX1 HCIFZ HMCUK HYE IAO IHR INH INR ITC KQ8 L6V M1P M48 M7S M~E O5R O5S OK1 OVT P2P PATMY PHGZM PHGZT PIMPY PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PTHSS PUEGO PYCSY RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS U2A UKHRP W2D WOQ WOW XSB AAYXX AFFHD CITATION 7X8 5PM |
| ID | FETCH-LOGICAL-c622t-26f086708650f79feeebccb4847f6b3e9e35d1b69a156e93a7986e15500abd983 |
| IEDL.DBID | RSV |
| ISICitedReferencesCount | 48 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000538058600013&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1471-2458 |
| IngestDate | Mon Nov 10 04:30:40 EST 2025 Tue Nov 04 02:05:38 EST 2025 Sun Nov 09 14:02:03 EST 2025 Tue Nov 11 10:27:18 EST 2025 Tue Nov 04 17:53:53 EST 2025 Tue Nov 18 19:58:42 EST 2025 Sat Nov 29 02:06:29 EST 2025 Sat Sep 06 07:21:13 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Prescribing trends Sedative-hypnotics Drug safety Benzodiazepines Drug utilization |
| Language | English |
| License | Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c622t-26f086708650f79feeebccb4847f6b3e9e35d1b69a156e93a7986e15500abd983 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://link.springer.com/10.1186/s12889-020-08984-z |
| PMID | 32487058 |
| PQID | 2409191245 |
| PQPubID | 23479 |
| PageCount | 9 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_27e305db272c43f7b1312e16d7ad42fc pubmedcentral_primary_oai_pubmedcentral_nih_gov_7268471 proquest_miscellaneous_2409191245 gale_infotracmisc_A627382774 gale_infotracacademiconefile_A627382774 crossref_citationtrail_10_1186_s12889_020_08984_z crossref_primary_10_1186_s12889_020_08984_z springer_journals_10_1186_s12889_020_08984_z |
| PublicationCentury | 2000 |
| PublicationDate | 20200601 2020-06-01 |
| PublicationDateYYYYMMDD | 2020-06-01 |
| PublicationDate_xml | – month: 6 year: 2020 text: 20200601 day: 1 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London |
| PublicationTitle | BMC public health |
| PublicationTitleAbbrev | BMC Public Health |
| PublicationYear | 2020 |
| Publisher | BioMed Central BioMed Central Ltd BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: BMC |
| References | MJ Panneman (8984_CR28) 2003; 20 CN Kaufmann (8984_CR55) 2018; 69 P Verger (8984_CR3) 2018; 137 K Mugunthan (8984_CR71) 2011; 61 N Takeshima (8984_CR75) 2016; 237 M Lader (8984_CR64) 2011; 106 CA Cadogan (8984_CR57) 2018; 84 A Benard-Laribiere (8984_CR77) 2017; 26 National Institute for Clinical Excellence (8984_CR47) 2004 S Schneeweiss (8984_CR29) 2005; 58 T Kurko (8984_CR34) 2018; 27 H Everitt (8984_CR49) 2014; 64 J Caro-Mendivelso (8984_CR35) 2015; 2 WB Mendelson (8984_CR63) 1992; 53 BJ Ng (8984_CR27) 2018; 35 8984_CR16 A Fourrier (8984_CR51) 2001; 57 American Geriatrics Society (8984_CR10) 2015; 2015 LB Gerlach (8984_CR13) 2019; 34 8984_CR11 F López-Muñoz (8984_CR1) 2011; 25 EM Marra (8984_CR76) 2015; 63 K Demyttenaere (8984_CR41) 2008; 110 JM Cloos (8984_CR74) 2015; 84 T Nordfjærn (8984_CR67) 2012; 37 M Guerlais (8984_CR12) 2015; 50 JM Cook (8984_CR69) 2007; 22 RL Gould (8984_CR70) 2014; 204 S Sakshaug (8984_CR73) 2017; 120 G Jackson (8984_CR6) 2014; 127 8984_CR9 P-A Dionne (8984_CR20) 2013; 64 JF Peterson (8984_CR21) 2014; 62 S Petitjean (8984_CR37) 2007; 22 CN Kaufmann (8984_CR56) 2016; 25 CM Sonnenberg (8984_CR2) 2012; 47 JS Albrecht (8984_CR53) 2018; 27 P Carrasco-Garrido (8984_CR5) 2007; 16 MM Ohayon (8984_CR43) 1998; 51 J Bourgeois (8984_CR24) 2012; 68 GE Simon (8984_CR52) 2006; 28 AF Jorm (8984_CR46) 2000; 24 E Holm (8984_CR68) 2012; 3 L Chen (8984_CR25) 2016; 16 MM Ohayon (8984_CR40) 2002; 63 J Brandt (8984_CR4) 2019; 26 J Hallas (8984_CR30) 2005; 14 A Koyama (8984_CR8) 2013; 61 EA Pek (8984_CR18) 2017; 12 8984_CR36 G Batty (8984_CR19) 2001; 6 8984_CR32 8984_CR33 JT Hanlon (8984_CR59) 2002; 50 C de las Cuevas (8984_CR65) 2003; 167 M Préville (8984_CR58) 2012; 31 J Haukka (8984_CR31) 2007; 63 M Linden (8984_CR39) 1999; 19 CF Johnson (8984_CR23) 2016; 66 SR Kjosavik (8984_CR44) 2009; 18 R Van Hulter (8984_CR42) 1998; 20 RB Weisberg (8984_CR17) 2007; 164 B Sivertsen (8984_CR50) 2010; 19 C Huerta (8984_CR72) 2016; 25 R Lagnaoui (8984_CR38) 2004; 60 G Salkeld (8984_CR26) 2000; 320 JHA Van der Heyden (8984_CR62) 2009; 18 J Brett (8984_CR45) 2018; 66 MP Vicente Sánchez (8984_CR66) 2013; 87 G Fond (8984_CR22) 2016; 233 S Madhusoodanan (8984_CR60) 2004; 3 S Alessi-Severini (8984_CR78) 2014; 2 M Olfson (8984_CR7) 2015; 72 JM Cook (8984_CR48) 2007; 22 KB Wolitzky-Taylor (8984_CR54) 2010; 27 H Park (8984_CR15) 2015; 71 FW Van der Waals (8984_CR61) 1993; 307 T Mura (8984_CR14) 2013; 23 |
| References_xml | – volume: 2 start-page: E208 year: 2014 ident: 8984_CR78 publication-title: CMAJ Open doi: 10.9778/cmajo.20130076 – volume: 20 start-page: 78 year: 1998 ident: 8984_CR42 publication-title: Pharm World Sci doi: 10.1023/A:1008636707219 – volume: 2015 start-page: 2227 issue: 63 year: 2015 ident: 8984_CR10 publication-title: J Am Geriatr Soc – volume: 64 start-page: 112 year: 2014 ident: 8984_CR49 publication-title: Br J Gen Pract doi: 10.3399/bjgp14X677176 – volume: 62 start-page: 2148 year: 2014 ident: 8984_CR21 publication-title: J Am Geriatr Soc doi: 10.1111/jgs.13057 – ident: 8984_CR11 – volume: 19 start-page: 132 year: 1999 ident: 8984_CR39 publication-title: J Clin Psychopharmacol doi: 10.1097/00004714-199904000-00007 – volume: 51 start-page: 273 year: 1998 ident: 8984_CR43 publication-title: J Clin Epidemiol doi: 10.1016/S0895-4356(97)00238-2 – volume: 50 start-page: 320 year: 2015 ident: 8984_CR12 publication-title: Subst Use Misuse doi: 10.3109/10826084.2014.980952 – volume: 27 start-page: 301 year: 2018 ident: 8984_CR53 publication-title: Am J Geriatr Psychiatry doi: 10.1016/j.jagp.2018.10.017 – volume: 61 start-page: 573 year: 2011 ident: 8984_CR71 publication-title: Br J Gen Pract doi: 10.3399/bjgp11X593857 – volume: 18 start-page: 1101 year: 2009 ident: 8984_CR62 publication-title: Pharmacoepidemiol Drug Saf doi: 10.1002/pds.1827 – volume: 26 start-page: 162 year: 2017 ident: 8984_CR77 publication-title: Pharmacoepidemiol Drug Saf doi: 10.1002/pds.4123 – start-page: 77 volume-title: Guidance on the Use of Zaleplon, Zolpidem and Zopiclone for the Short-term Management of Insomnia. Technology Appraisal Guidance year: 2004 ident: 8984_CR47 – volume: 27 start-page: 674 year: 2018 ident: 8984_CR34 publication-title: Pharmacoepidemiol Drug Saf doi: 10.1002/pds.4551 – volume: 57 start-page: 419 year: 2001 ident: 8984_CR51 publication-title: Eur J Clin Pharmacol doi: 10.1007/s002280100326 – volume: 60 start-page: 523 year: 2004 ident: 8984_CR38 publication-title: Eur J Clin Pharmacol doi: 10.1007/s00228-004-0808-2 – volume: 47 start-page: 293 year: 2012 ident: 8984_CR2 publication-title: Soc Psychiatry Psychiatr Epidemiol doi: 10.1007/s00127-011-0344-1 – volume: 66 start-page: e410 year: 2016 ident: 8984_CR23 publication-title: Brit J Gener Pract doi: 10.3399/bjgp16X685213 – volume: 307 start-page: 363 year: 1993 ident: 8984_CR61 publication-title: BMJ doi: 10.1136/bmj.307.6900.363 – volume: 120 start-page: 292 year: 2017 ident: 8984_CR73 publication-title: Basic Clin Pharmacol Toxicol doi: 10.1111/bcpt.12684 – volume: 127 start-page: 67 year: 2014 ident: 8984_CR6 publication-title: N Z Med J – volume: 87 start-page: 247 year: 2013 ident: 8984_CR66 publication-title: Rev Esp Salud Publica doi: 10.4321/S1135-57272013000300004 – volume: 31 start-page: 313 year: 2012 ident: 8984_CR58 publication-title: Can J Aging doi: 10.1017/S0714980812000232 – volume: 84 start-page: 1354 year: 2018 ident: 8984_CR57 publication-title: Br J Clin Pharmacol doi: 10.1111/bcp.13570 – volume: 23 start-page: 212 year: 2013 ident: 8984_CR14 publication-title: Eur Neuropsychopharmacol doi: 10.1016/j.euroneuro.2012.05.004 – volume: 22 start-page: 292 year: 2007 ident: 8984_CR37 publication-title: Int Clin Psychopharmacol doi: 10.1097/YIC.0b013e328105e0f2 – volume: 53 start-page: 4 issue: Suppl 12 year: 1992 ident: 8984_CR63 publication-title: J Clin Psychiatry – volume: 25 start-page: 554 year: 2011 ident: 8984_CR1 publication-title: J Anxiety Disord doi: 10.1016/j.janxdis.2011.01.002 – volume: 64 start-page: 331 year: 2013 ident: 8984_CR20 publication-title: Psychiatr Serv doi: 10.1176/appi.ps.201200089 – volume: 84 start-page: 273 year: 2015 ident: 8984_CR74 publication-title: Psychother Psychosom doi: 10.1159/000434755 – volume: 28 start-page: 374 year: 2006 ident: 8984_CR52 publication-title: Gen Hosp Psychiatry doi: 10.1016/j.genhosppsych.2006.05.008 – volume: 233 start-page: 2549 year: 2016 ident: 8984_CR22 publication-title: Psychopharmacology doi: 10.1007/s00213-016-4312-z – volume: 25 start-page: 56 year: 2016 ident: 8984_CR72 publication-title: Pharmacoepidemiol Drug Saf doi: 10.1002/pds.3825 – volume: 3 start-page: 299 year: 2012 ident: 8984_CR68 publication-title: Eur Geriatr Med doi: 10.1016/j.eurger.2012.04.007 – volume: 20 start-page: 833 year: 2003 ident: 8984_CR28 publication-title: Drugs Aging doi: 10.2165/00002512-200320110-00004 – volume: 16 start-page: 449 year: 2007 ident: 8984_CR5 publication-title: Pharmacoepidemiol Drug Saf doi: 10.1002/pds.1344 – volume: 63 start-page: 2074 year: 2015 ident: 8984_CR76 publication-title: J Am Geriatr Soc doi: 10.1111/jgs.13666 – volume: 68 start-page: 833 year: 2012 ident: 8984_CR24 publication-title: Eur J Clin Pharmacol doi: 10.1007/s00228-011-1188-z – volume: 66 start-page: 1180 year: 2018 ident: 8984_CR45 publication-title: J Am Geriatr Soc doi: 10.1111/jgs.15292 – volume: 71 start-page: 1429 year: 2015 ident: 8984_CR15 publication-title: Eur J Clin Pharmacol doi: 10.1007/s00228-015-1955-3 – volume: 63 start-page: 1069 year: 2007 ident: 8984_CR31 publication-title: Eur J Clin Pharmacol doi: 10.1007/s00228-007-0349-6 – ident: 8984_CR36 – ident: 8984_CR9 doi: 10.3390/jcm7020017 – volume: 12 start-page: 310 year: 2017 ident: 8984_CR18 publication-title: J Hosp Med doi: 10.12788/jhm.2739 – ident: 8984_CR32 – volume: 137 start-page: 328 year: 2018 ident: 8984_CR3 publication-title: Acta Psychiatr Scand doi: 10.1111/acps.12858 – ident: 8984_CR16 – volume: 237 start-page: 201 year: 2016 ident: 8984_CR75 publication-title: Psychiatry Res doi: 10.1016/j.psychres.2016.01.040 – volume: 26 start-page: e22 year: 2019 ident: 8984_CR4 publication-title: J Popul Ther Clin Pharmacol doi: 10.22374/1710-6222.26.1.3 – volume: 6 start-page: 252 year: 2001 ident: 8984_CR19 publication-title: Br J Clin Gov doi: 10.1108/14664100110408608 – volume: 27 start-page: 190 year: 2010 ident: 8984_CR54 publication-title: Depress Anxiety doi: 10.1002/da.20653 – volume: 320 start-page: 341 year: 2000 ident: 8984_CR26 publication-title: BMJ doi: 10.1136/bmj.320.7231.341 – volume: 3 start-page: 485 year: 2004 ident: 8984_CR60 publication-title: Expert Opin Drug Saf doi: 10.1517/14740338.3.5.485 – volume: 22 start-page: 1094 year: 2007 ident: 8984_CR69 publication-title: J Gen Intern Med doi: 10.1007/s11606-007-0205-5 – volume: 106 start-page: 2086 year: 2011 ident: 8984_CR64 publication-title: Addiction doi: 10.1111/j.1360-0443.2011.03563.x – volume: 167 start-page: 297 year: 2003 ident: 8984_CR65 publication-title: Psychopharmacology doi: 10.1007/s00213-002-1376-8 – volume: 63 start-page: 817 year: 2002 ident: 8984_CR40 publication-title: J Clin Psychiatry doi: 10.4088/JCP.v63n0912 – volume: 110 start-page: 84 year: 2008 ident: 8984_CR41 publication-title: J Affect Disord doi: 10.1016/j.jad.2008.01.011 – volume: 14 start-page: 455 year: 2005 ident: 8984_CR30 publication-title: Pharmacoepidemiol Drug Saf doi: 10.1002/pds.1063 – volume: 72 start-page: 136 year: 2015 ident: 8984_CR7 publication-title: JAMA Psychiat doi: 10.1001/jamapsychiatry.2014.1763 – volume: 16 start-page: 196 year: 2016 ident: 8984_CR25 publication-title: BMC Geriatr doi: 10.1186/s12877-016-0363-6 – volume: 164 start-page: 276 year: 2007 ident: 8984_CR17 publication-title: Am J Psychiatry doi: 10.1176/ajp.2007.164.2.276 – volume: 58 start-page: 323 year: 2005 ident: 8984_CR29 publication-title: J Clin Epidemiol doi: 10.1016/j.jclinepi.2004.10.012 – volume: 204 start-page: 98 year: 2014 ident: 8984_CR70 publication-title: Br J Psychiatry doi: 10.1192/bjp.bp.113.126003 – ident: 8984_CR33 – volume: 19 start-page: 36 year: 2010 ident: 8984_CR50 publication-title: J Sleep Res doi: 10.1111/j.1365-2869.2009.00769.x – volume: 61 start-page: 258 year: 2013 ident: 8984_CR8 publication-title: J Am Geriatr Soc doi: 10.1111/jgs.12093 – volume: 24 start-page: 7 year: 2000 ident: 8984_CR46 publication-title: Aust N Z J Public Health doi: 10.1111/j.1467-842X.2000.tb00715.x – volume: 34 start-page: 1833 year: 2019 ident: 8984_CR13 publication-title: J Gen Intern Med doi: 10.1007/s11606-019-05098-0 – volume: 35 start-page: 493 year: 2018 ident: 8984_CR27 publication-title: Drugs Aging doi: 10.1007/s40266-018-0544-4 – volume: 18 start-page: 572 year: 2009 ident: 8984_CR44 publication-title: Pharmacoepidemiol Drug Saf doi: 10.1002/pds.1756 – volume: 25 start-page: 637 year: 2016 ident: 8984_CR56 publication-title: Pharmacoepidemiol Drug Saf doi: 10.1002/pds.3951 – volume: 37 start-page: 1151 year: 2012 ident: 8984_CR67 publication-title: Addict Behav doi: 10.1016/j.addbeh.2012.05.017 – volume: 2 start-page: 80 year: 2015 ident: 8984_CR35 publication-title: J Epidemiol Res doi: 10.5430/jer.v2n1p80 – volume: 50 start-page: 26 year: 2002 ident: 8984_CR59 publication-title: J Am Geriatr Soc doi: 10.1046/j.1532-5415.2002.50004.x – volume: 69 start-page: 235 year: 2018 ident: 8984_CR55 publication-title: Psychiatr Serv doi: 10.1176/appi.ps.201700095 – volume: 22 start-page: 303 year: 2007 ident: 8984_CR48 publication-title: J Gen Intern Med doi: 10.1007/s11606-006-0021-3 |
| SSID | ssj0017852 |
| Score | 2.4853003 |
| Snippet | Background
The high prevalence and long-term use of benzodiazepines (BZDs) treatment are debated topics because of the risk they can cause to the patients.... Background The high prevalence and long-term use of benzodiazepines (BZDs) treatment are debated topics because of the risk they can cause to the patients.... The high prevalence and long-term use of benzodiazepines (BZDs) treatment are debated topics because of the risk they can cause to the patients. Despite the... Abstract Background The high prevalence and long-term use of benzodiazepines (BZDs) treatment are debated topics because of the risk they can cause to the... |
| SourceID | doaj pubmedcentral proquest gale crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Enrichment Source Index Database Publisher |
| StartPage | 818 |
| SubjectTerms | Analysis Antianxiety agents Benzodiazepines Biostatistics Consumption data Drug safety Drug utilization Drugs Environmental Health Epidemiology Global health Health Medicine Medicine & Public Health Prescribing trends Public Health Research Article Sedative-hypnotics Vaccine |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYl5FAoJX1Rt2lQodBDa7KWbT2OSWjoIYQeWshN6DFuF4Id1rs97Lk_PDOyvdQJpJcejMGShawZjWbk-T4x9kHHUBONXb4QwWCAEkRucGnI0RfR2i3ACJWAwhfq8lJfXZlvfx31RTlhAz3wMHDHWBdVMnqhRKjKRvmiLAQUMioXK9EEsr7o9UzB1Pj_QOlaTBAZLY97tMKUGiQod8voKt_OlqHE1n_fJt_Pk7zzszStQecH7OnoPPKTodPP2CNon7Mnw84bHwBFL9ifIc2VL1uOzh0PCWOZDAMnWoiedw330G471Iwt3FDaO3dtvPMsTyAXiDyuNj93jQ2oSU6nOWBz2NDFNSyj4wRS4ZSIwdcd3ov6Jftx_uX72dd8PGshD1KIdS5kg8GNwqteNMo0AOBD8BUuXo30JRgo61h4aRwGfGBKp4yWQPHNwvlodPmK7bVdC68ZDyL6xgnAyBMqGRsUtzIhoqPklZeFzFgxDb0NIxE5nYdxbVNAoqUdxGVRXDaJy24z9mn3zs1Aw_Fg7VOS6K4mUWinB6hYdlQs-y_FythH0gdLEx27F9yIV8CPJMoseyIJ1YTfVmXscFYTJ2iYFb-fNMpSEWW1tdBteovelMF4WVR1xtRM1WZdn5e0y1-JBVwRT48qMvZ5Uko7mp_-gaF58z-G5i17LNJcos2oQ7a3Xm3gHdsPv9fLfnWUZuItu4A2Xg priority: 102 providerName: Directory of Open Access Journals |
| Title | Trends in the consumption rates of benzodiazepines and benzodiazepine-related drugs in the health region of Lleida from 2002 to 2015 |
| URI | https://link.springer.com/article/10.1186/s12889-020-08984-z https://www.proquest.com/docview/2409191245 https://pubmed.ncbi.nlm.nih.gov/PMC7268471 https://doaj.org/article/27e305db272c43f7b1312e16d7ad42fc |
| Volume | 20 |
| WOSCitedRecordID | wos000538058600013&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: BioMed Central_OA刊 customDbUrl: eissn: 1471-2458 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017852 issn: 1471-2458 databaseCode: RBZ dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1471-2458 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017852 issn: 1471-2458 databaseCode: DOA dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1471-2458 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017852 issn: 1471-2458 databaseCode: M~E dateStart: 20010101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Engineering Database customDbUrl: eissn: 1471-2458 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017852 issn: 1471-2458 databaseCode: M7S dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com providerName: ProQuest – providerCode: PRVPQU databaseName: Environmental Science Database customDbUrl: eissn: 1471-2458 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017852 issn: 1471-2458 databaseCode: PATMY dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com/environmentalscience providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection (ProQuest) customDbUrl: eissn: 1471-2458 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017852 issn: 1471-2458 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1471-2458 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017852 issn: 1471-2458 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1471-2458 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017852 issn: 1471-2458 databaseCode: 8C1 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1471-2458 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017852 issn: 1471-2458 databaseCode: PIMPY dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1471-2458 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017852 issn: 1471-2458 databaseCode: RSV dateStart: 20011201 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9RAFB5sKyKIl6oYrcsIgg8aupkkc3lsS4tCuyytyvo0ZC6pCyUpm10f9tkf7jmTZCGtFPQhCcxMhsnkXGfOd4aQ99LZHNPYxWNmFTgolsUKVEMMtoiUxdgrJgJQ-FRMJnI2U9MOFNb00e79lmSQ1IGtJd9vQJJieA_D-Csls3i9RXZA3Ulkx_OL75u9AyFz1sNj_vreQAWFTP235fHtGMkbG6VB_5w8-b-RPyWPO3uTHrQE8ozc89UueXDW7ajvkkftuh1t4UjPye82SJbOKwqmIbUBoRnECsWkEg2tS2p8ta6Brtb-GoPmaVG5G2VxgMh4R91idbnprMVcUjwLArqDjk6v_NwVFCEuFMM46LKGZ5K_IN9Ojr8efY67kxpiyxlbxoyX4BoJuPJxKVTpvTfWmgxUX8lN6pVPc5cYrgpwF71KC6Ek9-gdjQvjlExfku2qrvwrQi1zpiyYB7_VZ9yVQCxCWQdmlhGGJzwiSf_ztO3SmONpGlc6uDOS63a6NUy3DtOt1xH5uHnnuk3icWfrQ6SJTUtMwB0K6sWl7vhZAwmDpHSGCWaztBQmSRPmE-5E4TJW2oh8QIrSKCZgeLbo0A7wkZhwSx9wxETBt2UR2Ru0BPa2g-p3PU1qrMKYuMrXq0aDLabA22ZZHhExINbB0Ic11fxnyCEuMMuPSCLyqSdZ3Qmv5o6pef1vzd-QhyxQPS5a7ZHt5WLl35L79tdy3ixGZEvMRLhLuMujZER2Do8n0_NRWBgZYRjuBZRNv5xNf4wCj_8Bvb5Gqw |
| linkProvider | Springer Nature |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9RAFD5oFSuIl1oxWnUEwQcNbibJTOaxiqXidhGt0rchc0ldKEnZ7Pqwz_5wz5kkC2mloA_LQmYyTCbnmvm-MwCvCmdzKmMXT7hVmKBYHit0DTHGIkVRTrziMhCFp3I2K05O1JeeFNYOaPdhSzJY6qDWhXjXoiUleA8n_JUqsnh9HW5k6LEIyPf124_N3oEscj7QY_5638gFhUr9l-3xZYzkhY3S4H8O7v3fzO_D3T7eZPudgDyAa77egVtH_Y76Dtzpvtuxjo70EH53IFk2rxmGhswGhmYwK4yKSrSsqZjx9bpBuVr7cwLNs7J2F67FgSLjHXOL1elmsI5zyegsCBwOB5qe-bkrGVFcGME42LLB_yTfhe8HH48_HMb9SQ2xFZwvYy4qTI0k_vJJJVXlvTfWmgxdXyVM6pVPc5cYoUpMF71KS6kK4Sk7mpTGqSJ9BFt1U_vHwCx3piq5x7zVZ8JVKCxSWYdhlpFGJCKCZHh52vZlzOk0jTMd0plC6G65NS63Dsut1xG82dxz3hXxuLL3e5KJTU8qwB0uNItT3euzRhFGS-kMl9xmaSVNkibcJ8LJ0mW8shG8JonSZCZwerbs2Q74kFRwS-8L4kThs2UR7I16onrbUfPLQSY1NREmrvbNqtUYiynMtnmWRyBHwjqa-rilnv8MNcQlVfmRSQRvB5HVvfFqr1iaJ__W_QVsHx4fTfX00-zzU7jNgwbQB6w92FouVv4Z3LS_lvN28Txo8B_Fi0G6 |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3di9QwEB_0lEM4_DiVq54aQfBBy23TNmkez49FcV0O_ODeQvPRc-Fol92uD_vsH-5M2l3snRyID6XQpCFJZyYzzfx-AXhROJsTjV084lZhgGJ5rHBpiNEXKYpy5BWXASg8kdNpcXqqTv5A8Yds982WZIdpIJamuj2au6pT8UIcLdGqUqoPp1wsVWTx-jrcyOjQIIrXv3zf7iPIIucbqMxf3xssR4G1_7JtvpwveWHTNKxF4zv_P4q7cLv3Q9lxJzj34Jqv92H3c7_Tvg973f881sGU7sOvLnmWzWqGLiOzAbkZzA0jsoklaypmfL1uUN7Wfk7J9Kys3YVncYDOeMfcYnW2bazDYjI6IwKbw4Ym537mSkbQF0bpHaxt8J7kD-Db-P3Xtx_i_gSH2ArO25iLCr-JxCsfVVJV3ntjrclwSayESb3yae4SI1SJYaRXaSlVITxFTaPSOFWkD2Gnbmp_AMxyZ6qSe4xnfSZchUIklXXofhlpRCIiSDYfUtue3pxO2TjXIcwphO6mW-N06zDdeh3Bq-07847c48rab0g-tjWJmDs8aBZnutdzjaKNFtQZLrnN0kqaJE24T4STpct4ZSN4SdKlyXxg92zZoyBwkETEpY8FYaVwbFkEh4OaqPZ2UPx8I5-aiihXrvbNaqnRR1MYhfMsj0AOBHfQ9WFJPfsRuMUlsf_IJILXG_HVvVFbXjE1j_6t-jPYPXk31pOP00-P4RYPCkD_tQ5hp12s_BO4aX-2s-XiaVDm3_3CSp4 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Trends+in+the+consumption+rates+of+benzodiazepines+and+benzodiazepine-related+drugs+in+the+health+region+of+Lleida+from+2002+to+2015&rft.jtitle=BMC+public+health&rft.au=Torres-Bondia%2C+F.&rft.au=de+Batlle%2C+J.&rft.au=Galv%C3%A1n%2C+L.&rft.au=Buti%2C+M.&rft.date=2020-06-01&rft.pub=BioMed+Central&rft.eissn=1471-2458&rft.volume=20&rft_id=info:doi/10.1186%2Fs12889-020-08984-z&rft_id=info%3Apmid%2F32487058&rft.externalDocID=PMC7268471 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2458&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2458&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2458&client=summon |